Resources from the same session
LBA4 - Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial
Presenter: Robert Motzer
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
LBA5 - Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)
Presenter: Jean-Pascal Machiels
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
LBA6 - Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)
Presenter: Sapna Patel
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
LBA7 - Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study
Presenter: Myriam Chalabi
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA4, LBA5, LBA6, LBA7 - The medical oncologist point of view
Presenter: James Larkin
Session: Presidential Symposium II
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Presidential Symposium II
Resources:
Slides
Webcast